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Clinicians should not only know how many patients will benefit from alpha-blocker therapy
but should also be able to identify who will benefit. We studied the changes in patient symp-
toms following alpha-blocker therapy and the predictors of symptom improvement in clinical
practice.
Design
This was a single-arm, open-label observational cohort study with a 6-week follow-up.
Setting
Twenty-two pharmacies in the Netherlands.
Participants
Patients were eligible for inclusion if they attended a pharmacy with a new prescription for
an alpha-blocker from a general practitioner or urologist.
Primary and secondary outcomes
Outcomes were assessed using the International Prostate Symptom Score (IPSS), Overac-
tive Bladder Questionnaire Short Form (OAB-q SF), and Patient Global Impression of
Improvement (PGI-I). Demographic, disease-related, and drug-related information were col-
lected to identify predictors of symptom improvement. These predictors were then assessed
by logistic and linear regression analyses of both the original data set and an imputed data
set that accounted for the missing variables.
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Results
During the study, 37% of patients with lower urinary tract symptoms perceived clear symp-
tomatic improvement based on the results of the PGI-I. Improvement was more likely in
those who still used alpha-blockers at the end of the 6-week study period and in those who
used multiple medications. Although symptom scores decreased significantly on the IPSS
and OAB-q SF, the only predictor of change was the pretreatment symptom severity.
Conclusions
Approximately one-third of our cohort perceived symptom improvement on alpha-blocker
therapy. However, we identified no clear predictors of who might benefit from alpha-blocker
treatment, indicating that alpha-blockers should still be prescribed on a trial basis.
Introduction
Alpha-blockers are the first step of drug treatment for men with moderate to severe lower uri-
nary tract symptoms (LUTS).[1,2] Current guideline recommendations are based on the effi-
cacy of alpha-blockers assessed by symptom scores in randomized controlled trials.[2–4] In
daily practice, however, patients and clinicians are more interested in achieving symptom
improvements that reflect changes in the subjective appraisal of symptoms, which may not be
reflected on these symptom scores. Predicting the likelihood of improvement is difficult for cli-
nicians because the randomized controlled trials on which they rely for guidance tend to
report mean changes in symptom scores rather than the number of patients who experience
improvement. Moreover, the inability to determine who will benefit from alpha-blocker treat-
ment is confounded by the multifactorial origin of LUTS in the male population. Clinicians
must therefore rely on the general advice to start alpha-blockers when treatment is requested.
[3–5] Information that helps clinicians to identify those patients who are most likely to experi-
ence improvement after alpha-blocker use would be clinically relevant.
In this study, we aimed to assess symptom improvement following alpha-blocker use and to
identify the predictors of that improvement in routine clinical practice.
Materials and methods
We performed a single-arm, open-label, observational cohort study with a 6-week follow-up
from January 2016 to April 2018. The primary settings were 22 pharmacies in the Northern
part of the Netherlands. Patients were eligible for inclusion if they attended a pharmacy with a
new prescription for an alpha-blocker to treat LUTS, provided they had not been prescribed
an alpha-blocker in the preceding 12 months. The following exclusion criteria were also
checked by the pharmacy: indwelling urinary catheter use, urolithiasis, and status as a first pre-
scription as part of combination therapy (i.e., alpha-blocker combined with an anticholinergic
drug or a 5-alpha reductase inhibitor).
Participants completed a questionnaire at baseline, and we subsequently obtained data
from a follow-up questionnaire and from the records of the patient’s general practitioner (GP)
or urologist, depending on the prescriber, as well as the pharmacist. The requirements of the
STROBE statement were followed when reporting the study.[6] The Medical Ethical Commit-
tee of the University Medical Center Groningen approved the study (METc 2016.122) and all
participants provided signed informed consent before inclusion.
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Patient questionnaire
The baseline questionnaire included questions about age, duration of LUTS, and previous sur-
gery for LUTS. It also included the International Prostate Symptom Score (IPSS) and the Over-
active Bladder Questionnaire Short Form (OAB-q SF). The IPSS consists of seven questions
that assess urinary symptoms,[7] giving total scores of 0–35, with higher scores indicating
worse symptoms. The OAB-q SF assesses how bothersome overactive bladder symptoms are
for the patient.[8] It consists of six questions, with total scores ranging from 0 to 100 and
higher scores indicating greater bother from symptoms. The follow-up questionnaire included
the IPSS, the OAB-q SF, and the Patient Global Impression of Improvement (PGI-I),[9]
together with questions about current alpha-blocker use and (if relevant) reasons for discon-
tinuing therapy.
GP, urologist, and pharmacist questionnaires
GPs and urologists were asked to provide data about comorbidities and physical examinations.
Pharmacists were asked to provide a list of concomitant medication, from which we extracted
data about the number of drugs currently used. We selected specific drugs with the potential
to affect LUTS, using the Anatomical Therapeutic Chemical Classification System for categori-
zation (e.g., antipsychotics, tricyclic antidepressants, selective serotonin reuptake inhibitors,
Parkinson’s disease medication, classic antihistamines, calcium antagonists, and opiates).[4]
Outcomes. The main outcomes were clear symptom improvement, assessed by the PGI-I,
as well as the predictors of that improvement. For this we categorized the responses “much
better” or “very much better” as clear improvement and all other categories as no clear improve-
ment. Secondary outcomes were the changes in symptoms, assessed by the IPSS and OAB-q, as
well as the predictors of those changes. For this, we compared the responses after 6 weeks of
therapy with the baseline scores.
Handling of missing data
Missing value analysis suggested that data were missing at random for approximately 5% of
baseline data and 35% of follow-up data. Multiple imputation was performed on this dataset
with 35 imputations and 20 iterations, using fully conditional specification and predictive
mean matching. Patient characteristics, symptom scores, and medical information were used
in the imputation model. Analyses performed on the imputed datasets were pooled. All analy-
ses were performed on both the original complete data and the imputed data.
Statistical analyses
Baseline characteristics are presented for the original data. Percentages experiencing clear
improvement and the change in symptom severity are presented for both the original and
imputed data. We assessed the change in symptoms following alpha-blocker use by comparing
baseline and follow-up scores on the IPSS and AOB-q, using paired t-tests. All analyses were
performed using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp., Armonk, NY,
USA). An alpha of<0.05 was considered statistically significant in all analyses, unless other-
wise stated.
To explore the possible predictors of clear improvement, we performed univariable logistic
regression, setting clear improvement as the dependent variable. All assumptions for the test
were met. We included the following variables as potential predictors: IPSS score, IPSS storage
sub-score, IPSS voiding sub-score, OAB-q SF score, age category (i.e., <60, 60–70, or >70
years), symptom duration (i.e., <6, 6–24, or >24 months), continued alpha-blocker use,
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comorbidities (i.e., yes or no), prescriber (i.e., GP or urologist), prostate abnormalities, pelvic
floor abnormalities, number of co-medications (i.e., 0–1, 2–5, or�6, based on tertiles), and
use of medication with a potential effect on LUTS. Variables with a p-value <0.25 in the uni-
variate analyses were included in the multivariable regression analyses by a non-automated
step-wise forward selection strategy. In the multivariable analyses, we used ten events per vari-
able to obtain the maximum number of independent variables for inclusion.[10] Model fit was
assessed by the Hosmer–Lemeshow test, explained variance by the Nagelkerke R2, and dis-
crimination was assessed by the area under the receiver operating characteristic curve.
Linear regression analyses were performed, with the changes in the IPSS and OAB-q scores
between baseline and follow-up set as the outcomes of interest, using the predictors and vari-
able selection procedures described above. Dummy variables were created for categorical vari-
ables with two or more categories. The assumptions for the test were met and the maximum
number of independent variables that could be included was determined based on accepted
guidelines.[11] The explained variance was assessed based on the adjusted R2. Because a higher
IPSS score indicates more symptoms, regression coefficients of improvement will have a nega-
tive sign. Subgroup regression analyses were performed for participants who had their therapy
prescribed by a GP and had complete data.
Results
Of the 258 screened patients, 251 met the inclusion criteria. One patient did not provide
informed consent and two died during follow-up, leaving 248 participants for analysis. Com-
plete data were obtained for 119 cases, and their baseline characteristics are presented in
Table 1. An overview of the medication that was used by the patients is given in S1 Table. Most
patients reported moderate or severe symptoms, reported that symptoms had been present for
over 24 months, and received their prescription from a GP (84%). Although most were still
taking therapy at 6 weeks (n = 89; 75%), several had stopped therapy because of ineffectiveness
(n = 12), side effects (n = 9), or lack of awareness that the medication should be continued
(n = 9).
Primary outcome: Clear improvement
In both the original and imputed data sets, 37% of participants reported clear symptom
improvement. For the original data, currently using alpha-blockers and currently using at least
six other medications both predicted clear improvement in both the univariate and multivari-
ate analyses (Table 2). However, we found no associations for any other potential predictor.
The imputed data analyses also yielded no significant predictors of clear improvement. The
multivariate models were similar for the original and imputed data, with explained variances
(Nagelkerke R2) of 20.6% and 10.9%, respectively. Model fit was better when based on the orig-
inal data (Table 2).
Secondary outcomes: Change in symptom severity
The mean improvements in the IPSS were 6.3 points (95%CI 5.1–7.6) for the original data and
5.4 points (95%CI 4.0–6.7) for the imputed data. In the multivariate regression, multicollinear-
ity existed between the pretreatment IPSS sub-scores and IPSS total score, so we only included
the IPSS total score as a predictor (based on the adjusted R2). Univariate regression analysis
using the original data showed that men receiving at least six co-medications had greater
symptom improvements; but, this was not confirmed in the multivariate regression analysis
(Table 3). Multivariate analyses on both datasets showed that higher baseline symptom severity
was associated with greater improvements after 6 weeks, but there were no other independent
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predictors of change in IPSS scores. We included prostate abnormalities in the model using
imputed data, but not in the model using original data. The percentages of variance explained
by the original and imputed data were 30.0% and 33.5%, respectively.




Age, (mean ± SD) 66.3 ± 9.3 y
Age category, N (%)
<60 y 31 (26.1)
60–70 y 47 (39.5)
>70 y 41 (34.5)
Duration of complaints, N (%)
�6 months 40 (33.6)
>6 months to�24 months 15 (12.6)
>24 months 64 (53.8)





Storage sub-score (mean ± SD) 8.6 ± 3.2
Voiding sub-score (mean ± SD) 10.8 ± 5.1
OAB-q SF (mean ± SD) 39.7 ± 19.9
Surgery for LUTS (%) 1 (0.8)




Prostate abnormal, N (%)
Normal 38 (31.9)
Increased size 51 (42.9)
Decreased size 3 (2.5)
Not examined 27 (22.7)
Examination of pelvic floor, N (%)
Hypertonic 7 (5.9)
Not hypertonic 54 (45.4)
Not determined 34 (28.6)
Not examined 24 (20.2)




Co-medication with effect on LUTS, N (%) 15 (12.6)
� Comorbidities included diabetes, stroke, myocardial infarction, and heart failure.
Abbreviations: IPSS, International Prostate Symptom Score; LUTS, Lower Urinary Tract Symptoms; OAB-q SF,
Overactive Bladder Questionnaire Short Form; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0220417.t001
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Finally, the OAB-q SF score improved by 12.0 points (95%CI 8.8–15.2) in the original data
and by 11.7 points (95%CI 8.2–15.1) in the imputed data. In both datasets, only pretreatment
symptom scores were significant predictors of change in the OAB-q in the univariate regres-
sion analyses (Table 4). Greater baseline symptom severity was associated with greater symp-
tom improvements. In the multiple regression analyses, the OAB-q SF pretreatment score
remained the only predictor of improvement. The multivariate model using original data
included current alpha-blocker use and the model using imputed data included the presence
of comorbidities. The percentages of variance explained by the original and imputed data were
28.7% and 36.0%, respectively.
Subgroup analyses
Analyses on participants who received their first prescription from a GP (n = 100; 84%)
showed similar results to those of the total group (S2–S4 Tables). Here also 37% of participants
Table 2. Predictors of clear PGI-I improvement.
Original data (complete cases) Imputed data (pooled outcomes)
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age (ref = <60 y)
60–70 y 1.70 (0.66;4.38) NI 1.23 (0.55;2.71) NI
>70 y 0.98 (0.36;2.65) NI 0.98 (0.45;2.14) NI
Duration of complaints (ref = <6 months)
6–24 months 0.55 (0.16;1.91) 0.61 (0.16;2.34) 0.58 (0.21;1.62) 0.59 (0.20;1.80)
> 24 months 0.50 (0.22;1.14) 0.49 (0.20;1.18) 0.64 (0.31;1.32) 0.66 (0.31;1.40)
IPSS sum score 0.99 (0.94;1.05) NI 0.99 (0.94;1.04) NI
IPSS storage baseline 0.98 (0.88;1.10) NI 0.96 (0.87;1.06) NI
IPSS voiding baseline 1.00 (0.93;1.07) NI 0.99 (0.93;1.06) NI
OAB-q SF baseline 1.00 (0.98;1.02) NI 1.00 (0.99;1.02) NI
Still using α-blockers at 6 weeks (ref = no) 5.31 (1.71;16.47) 5.70 (1.73;18.84) 2.21 (0.75;6.52) 2.42 (0.80;7.30)
Comorbidity (ref = no) 1.20 (0.53;2.70) NI 1.29 (0.55;2.98) NI
Prescriber (ref = GP) 0.99 (0.36;2.75) NI 0.98 (0.41;2.33) NI
Prostate abnormal (ref = no)
Increased size 0.94 (0.39;2.24) NI 0.95 (0.43;2.08) NI
Decreased size 3.43 (0.28;41.32) NI 1.27 (0.18;9.01) NI
Not examined 1.01 (0.36;2.80) NI 0.92 (0.32;2.64) NI
Examination of pelvic floor (ref = hypertonic)
Not hypertonic 4.13 (0.46;36.69) NI 1.36 (0.17;11.01) NI
Not determined 3.27 (0.35;30.46) NI 1.36 (0.27;9.97) NI
Not examined 3.60 (0.37;34.93) NI 1.19 (0.19;10.24) NI
Number of co-medication (ref = 0–1)
2–5 1.56 (0.66;3.70) 1.27 (0.51;3.17) 1.13 (0.38;3.31) 1.03 (0.32;3.29)
�6 3.89 (1.35;11.25) 3.80 (1.23;11.70) 2.19 (0.80;5.96) 2.28 (0.76;6.82)
Co-medication with an effect on LUTS (ref = no) 0.83 (0.27;2.62) NI 1.62 (0.46–5.75) NI
Nagelkerke R2 = 20.6%
HL test = 0.87
AUC = 0.73
Nagelkerke R2 = 10.9%
HL test = 0.77
AUC = 0.66
Abbreviations: AUC, Area Under the Curve; CI, confidence interval; GP, General Practitioner; HL, Hosmer–Lemeshow; IPSS, International Prostate Symptom Score;
LUTS, Lower Urinary Tract Symptoms; NI, Not included; OAB-q SF, Overactive Bladder Questionnaire Short Form; OR, odds ratio; PGI-I, Patient Global Impression
of Improvement.
https://doi.org/10.1371/journal.pone.0220417.t002
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reported clear symptom improvement. In this subgroup patients with symptoms for over 24
months were less likely to show clear improvement compared to those with symptoms for less
than 6 months (OR 0.36 95% CI 0.13–0.98).
Discussion
The PGI-I results showed that about one in three men with LUTS perceived clear symptom
improvement by 6 weeks of starting an alpha-blocker, implying that two in three men
Table 3. Predictors of IPSS improvement.
Original data (complete cases) Imputed data (pooled outcomes)
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
IPSS change 95% CI IPSS change 95% CI IPSS change 95% CI IPSS change 95% CI
Constant 0.28 (-4.58;5.14) 3.22 (-1.31;7.75)
Age (ref = <60 y)
60–70 y 1.13 (-2.09;4.35) NI 0.92 (-1.59;3.43) NI
>70 y 0.82 (-2.49;4.14) NI 1.40 (-1.22;4.02) NI
Duration of complaints (ref = <6 months)
6–24 months 1.04 (-3.18;5.26) NI 0.18 (-3.02;3.37) NI
>24 months 0.20 (-2.61;3.01) NI -0.39 (-2.77;1.99) NI


















OAB-q SF baseline -0.06 (-0.13;-
0.01)
0.06 (-0.01;0.13) -0.09 (-0.14;-
0.04)
0.04 (-0.02;0.09)
Still using α-blockers at 6 weeks (ref = no) -1.03 (-3.96;1.90) NI -0.70 (-3.99;2.59) NI
Comorbidity (ref = no) -1.99 (-4.76;0.78) -0.12 (-2.96;2.72) 0.11 (-2.61;2.84) NI
Prescriber (ref = GP) 2.91 (-0.53;6.34) 2.42 (-0.55;5.38) 1.92 (-0.79;4.62) 1.28 (-1.10;3.66)
Prostate abnormal (ref = no)
Increased size 0.33 (-2.66;3.31) NI 0.28 (-2.94;3.49) 0.24 (-2.36;2.83)
Decreased size 4.40 (-3.96;12.77) NI 2.94 (-2.91;8.79) 1.47 (-3.66;6.60)
Not examined 0.66 (-2.84;4.17) NI 0.42 (-3.06;3.90) 0.27 (-2.55;3.08)
Examination of pelvic floor (ref = hypertonic)
Not hypertonic 1.01 (-4.60;6.61) NI -0.95 (-5.68;3.77) NI
Not determined 2.09 (-3.70;7.88) NI 0.27 (-5.25;5.80) NI
Not examined 2.32 (-3.68;8.31) NI 0.33 (-5.17;5.83) NI
Number of co-medications (ref = 0–1)
2–5 -0.43 (-3.13;2.28) 0.19 (-2.42;2.80) -0.60 (-3.52;2.32) -0.08 (-2.15;2.31)
�6 -5.60 (-9.03;-
2.18)
-2.20 (-6.03;1.62) -3.30 (-7.89;1.28) -1.05 (-4.09;1.99)
Co-medication with an effect on LUTS
(ref = no)
0.92 (-2.92;4.75) NI 2.00 (-1.69;5.69) NI
Adjusted R2 = 30.0% Adjusted R2 = 33.5%
Negative regression coefficients indicate improvement of symptoms.
�NI due to multicollinearity.
Abbreviations: CI, confidence interval; GP, General Practitioner; IPSS, International Prostate Symptom Score; NI, Not included; OAB-q SF, Overactive Bladder
Questionnaire Short Form.
https://doi.org/10.1371/journal.pone.0220417.t003
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experienced no clear improvement. Current use of an alpha-blocker and current use of at least
six additional medications predicted clear improvement, but only in the model using original
data. Although symptoms measured with the IPSS and OAB-q SF decreased significantly by 6
weeks, only pretreatment symptom severity predicted this change. Measures of explained vari-
ance for these models suggested that factors not assessed in this study predicted the observed
symptom improvement following alpha-blocker use. We believe that this information is rele-
vant to pretreatment counseling.
Table 4. Predictors of OAB-q SF improvement.
Original data (complete cases) Imputed data (pooled outcomes)
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
OAB-q SF
change
95% CI OAB-q SF
change
95% CI OAB-q SF
change
95% CI OAB-q SF
change
95% CI
Constant 8.53 (-1.00;18.06) 8.80 (0.43;17.17)
Age (ref = <60 y)
60–70 y 3.59 (-4.46;11.63) NI 2.96 (-3.82;9.75) NI
>70 y 2.16 (-6.11;10.44) NI 3.32 (-3.99;10.62) NI
Duration of complaints (ref = <6
months)
6–24 months 3.63 (-6.90;14.16) NI 4.28 (-5.01;13.56) NI
>24 months 2.68 (-4.33;9.69) NI 3.62 (-3.01;10.24) NI
IPSS sum score -0.74 (-1.19;-0.30) 0.18 (-0.33;0.68) -0.74 (-1.17;-0.30) 0.23 (-0.23;0.68)
IPSS storage baseline -1.26 (-2.22;-0.31) NI� -1.31 (-2.24;-0.37) NI�
IPSS voiding baseline -0.83 (-1.44;-0.22) NI� -0.75 (-1.30;-0.20) NI�
OAB-q SF baseline -0.49 (-0.62;-0.35) -0.50 (-0.66;-
0.33)
-0.58 (-0.72;-0.45) -0.61 (-0.77;-
0.45)
Still using α-blockers at 6 weeks
(ref = no)
-4.46 (-11.74;2.83) -3.06 (-9.30;3.18) -4.17 (-11.35;3.01)
Comorbidity (ref = no) 0.49 (-6.50;7.47) NI 5.52 (-2.32;13.36) 6.82 (-1.29;14.93)
Prescriber (ref = GP) 4.57 (-4.08;13.22) NI 3.65 (-4.09;11.40) NI
Prostate abnormal (ref = no)
Increased size 3.45 (-4.00;10.90) NI 1.28 (-6.77;9.32) NI
Decreased size 11.90 (-8.95;32.75) NI 4.27 (-11.65;20.18) NI
Not examined 2.02 (-6.73;10.77) NI -0.45 (-10.13;9.23) NI
Examination of pelvic floor
(ref = hypertonic)
Not hypertonic -2.02 (-15.92;11.88) NI -3.67 (-16.63;9.29) NI
Not determined 4.52 (-9.84;18.88) NI -0.04 (-13.61;13.53) NI
Not examined 0.26 (-14.60;15.12) NI -1.82 (-15.96;12.33) NI
Number of co-medications (ref = 0–1)
2–5 -4.48 (-11.44;2.49) -1.94 (-7.98;4.10) -3.42 (-11.27;4.43) -3.46 (-10.07;3.14)
�6 -8.51 (-17.34;0.32) -3.51 (-11.68;4.66) -5.76 (-15.00;3.48) -5.33 (-13.94;3.28)
Co-medication with an effect on
LUTS (ref = no)
-6.87 (-16.37;2.64) -3.18 (-11.43;5.07) 1.20 (-7.44;9.84) NI
Adjusted R2 = 28.7% Adjusted R2 = 36.0%
Negative regression coefficients indicate improvement of symptoms.
�NI due to multicollinearity.
Abbreviations: CI, confidence interval; GP, General Practitioner; IPSS, International Prostate Symptom Score; LUTS, Lower Urinary Tract Symptoms; NI, Not included;
OAB-q SF, Overactive Bladder Questionnaire Short Form.
https://doi.org/10.1371/journal.pone.0220417.t004
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Although currently use of alpha-blockers and six or more medications were both significant
predictors of clear improvement in the analysis of original data, they did not remain predictors
in the analysis of imputed data, despite there being similar trends in the odds ratios. The
increased odds indicated that clear improvement was more likely for those participants who
still used alpha-blockers after 6 weeks. However, no such relationship existed between current
alpha-blocker use and the more quantitative measures of improvement (i.e., the IPSS and
OAB-q SF), suggesting that any observed improvements in symptoms could not be attributed
to changes in either the frequency of urination or episodes of incontinence.
It is difficult to explain why participants who took more medications were more likely to
experience clear improvement. One explanation could be that participants who are used to
taking medication are more likely to include it in their regimens, improving the effectiveness
of alpha-blocker therapy. Supporting this, it has been shown that drug adherence is related to
concomitant use of other medications.[12–14] The present study did not monitor actual
intake, however, so we cannot comment with certainty. Another explanation is that other
types of medication lead to improvement of LUTS, however this is less likely. First of all, other
medication was initiated before baseline, and remained unchanged during the observation
period. Secondly, in our analyses we looked at known specific drugs with the potential to affect
LUTS and found no relation with change in symptoms, although we cannot rule out that there
are other types of drugs that have an influence on LUTS.
Only pretreatment scores predicted improvements in the IPSS and OAB-q SF, with the data
indicating that participants with more severe symptoms had greater benefit from alpha-
blocker treatment. Alternatively, we must consider that this may have been caused by a ceiling
effect or regression to the mean, which would have a greater influence in participants with
higher baseline scores. No other predictors could be identified. Nevertheless, our findings
regarding pretreatment scores are consistent with those of similar studies in secondary care,
[15,16] which additionally showed that prostate volume predicted outcomes. Another study
produced contradictory findings that there was no relationship,[17] instead proposing that
intravesical protrusion of the prostate predicted improvement, as reported elsewhere.[18]
However, we restricted our data collection to those characteristics that are readily available to
GPs, and neither the prostate volume nor the intravesical prostatic protrusion is routinely
measured in general practice.
In many countries, men with LUTS typically consult their GPs first, yet we could find no
studies referring to symptom improvement following alpha-blocker use in the primary care
setting. We therefore included participants who received their first prescription from either a
GP (n = 100; 84%) or a urologist (n = 19; 16%). In the subgroup analysis of participants who
were prescribed alpha-blockers by a GP, the results were comparable to those for the total
group. Unfortunately, the subgroup of participants receiving prescriptions from a urologist
was too small for separate analysis or comparison.
Finally, we showed that 70% of participants had persevered with their treatment by the end
of the study. This finding is consistent with that reported in another study, in which 73% per-
severed with treatment beyond 6 weeks.[19] Other studies have also indicated that approxi-
mately 35%–40% persist with therapy beyond 12 months, indicating that discontinuation is
most likely in the first few weeks or months after initiation.[19,20] Future studies should fur-
ther assess the reasons for persistence with alpha-blockers.
A major limitation of this study is the absence of a control group. Another limitation is that
the actual intake of medication was not monitored, which makes it impossible to know the
true effect of compliance with alpha-blocker therapy. Nevertheless, both results must be inter-
preted in the context that the study was designed to reflect real-life settings. Only including
participants who visited a pharmacy may also have led to selective inclusion by inadvertently
Symptom improvement and predictors associated with improvement after 6 weeks of alpha-blocker therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0220417 July 25, 2019 9 / 12
excluding housebound participants who were unable to visit the pharmacy. This small popula-
tion is likely to be older and to have more severe symptoms than our sample, limiting the gen-
eralizability of our results. A final limitation is that there was a significant amount of missing
data, with follow-up data missing for 35% and incomplete data available for 50%. Although
multiple imputation for the missing values allowed us to perform analyses on the complete
sample, the results of analyses were comparable for both data sets, albeit with small differences
found between factors included in the multivariate model.
In conclusion, slightly more than one-third of our cohort perceived clear improvement
after alpha-blocker therapy. Clinicians can use this information when counseling patients
about the risks and benefits of therapy. Overall, however, the study provides little additional
information to guide clinicians on who will benefit most from alpha-blocker treatment. As
such, advice in existing guidelines should continue to be followed, with alpha-blocker therapy
trialed for all men with moderate to severe LUTS who request treatment.
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